

# Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

Senthil Rajappa, Krishna Mohan  
Mallavarapu, Sadashivudu  
Gundeti, Tara Roshni Paul,  
Rachel Thomas Jacob,  
Raghunadharao Digumarti

Nizam's Institute of Medical  
Science is a Premier Institute,  
Hyderabad, Andhra Pradesh, India

## Address for correspondence:

Dr. Senthil Rajappa,  
Department of Medical  
Oncology, Nizam's Institute of  
Medical Sciences, Hyderabad,  
Andhra Pradesh, India.  
E-mail: sirishasenthil@rediffmail.com

## ABSTRACT

Imatinib has shown unprecedented success in the treatment of chronic myeloid leukemia (CML). However, over few years there have been reports regarding the primary and secondary resistance to Imatinib dampening the overall outcome in CML patients. In this study we have tried to assess the effect of dose escalation in patients resistant to standard dose of Imatinib and correlate it with presence of ABL kinase domain (KD) mutations. There were 90 patients resistant to imatinib, out of which 29 patients were identified with KD mutations. The most common mutation was T315I, 9 out of 29 patients had it. 35 (38%) responded to dose escalation and had 67% event free survival (EFS) at estimated 2 years. Our results showed that dose escalation can overcome resistance in some patients especially those in cytogenetic failure.

**Key words:** Chronic myeloid leukemia, imatinib, kinase domain mutations and responses

## INTRODUCTION

The discovery of imatinib mesylate (IM), a BCR ABL tyrosine kinase inhibitor (TKI) has dramatically altered the natural history of chronic myeloid leukemia (CML).<sup>[1]</sup> When the ELN and NCCN guidelines to monitor disease are applied, a third of all chronic phase CML (CP CML) patients are likely to be categorized as resistant to IM 400 mg.<sup>[2]</sup> Resistance can result from BCR ABL dependent mechanisms through mutations in the ABL kinase domain (KD) or those independent of the BCR ABL domain.<sup>[3]</sup>

For patients with resistance, IM dose escalation, 2<sup>nd</sup> generation TKIs (Dasatinib and Nilotinib), allo geneic stem cell transplantation SCT are options. There is conflicting data on the efficacy of dose escalation in patients resistant to IM 400 mg.<sup>[4-6]</sup> Due to financial reasons IM dose escalation remains the only option for most patients in our country. IM resistance mutations can help make a rational decision for patients with resistance. This analysis aimed at

analyzing KD mutations and response to dose escalation for patients in CP-CML at resistance to standard dose IM.

## PATIENTS AND METHOD

All the patients who had loss of response or no response to imatinib were included in the study. All these patients underwent imatinib resistant mutation analysis (IRMA) and dose escalation of imatinib from 400mg to 800mg once a day. These patients were then followed up and their response and survival analysis was done.

## RESULTS

There were 90 patients with a median age of 36 years (range, 18-65). The baseline characteristics of all patients is summarized in Table 1.

Twenty-nine (32.2%) patients had detectable KD mutations. These mutations are shown in Figure 1. The most common mutation was T315I in 9 (31%) patients. Thirteen (12.2%) of all patients (38% of all mutations) had a P loop mutation. N374Y is a novel mutation has not been reported before. No clinical or laboratory factors predicted for detection of KD mutation.

## Response to dose escalation

All patients with resistance were escalated from 400 mg to 800 mg. The response to dose escalation is in Table 2.

## Access this article online

### Quick Response Code:



Website:  
www.ijmpo.org

DOI:  
10.4103/0971-5851.123750

90 patients were followed-up for response, event free survival (EFS), transformation-free survival (TFS) and overall survival (OS). The median time to cytogenetic response was 11 months (range, 6-18). Predictors for achieving a major cytogenetic response (MCR) have been shown in Table 3.

### Event free, transformation free and OS

At a median follow-up of 18 months (range, 3-40), 35 patients (39%) were event free and 84 patients (93%) are alive. The estimated 2 year EFS and TFS were 34% and 86%. The following are the events in 55 patients (61%): failure to achieve complete haematological response: 37 (67.2%), loss of hematologic response: 2 (3.6%), failure to achieve cytogenetic response: 7 (12.7%), progression to accelerated phase/blast crises: 3 (5.4%) and deaths: 6 (11%). Predictors of EFS are summarized in Table 4.

For patients with hematologic failure, the estimated 2-year EFS and TFS were 22 and 74% respectively. For those with cytogenetic failure, the 2-year EFS and TFS were 73 and 95% respectively. This EFS difference was significant,  $P = 0.0018$ . The median EFS for those who achieved MCR to dose escalation have not been reached and the projected 2 year EFS is 67%. Patients with cytogenetic failure who achieved a MCR had more sustained responses compared to those with hematologic failures with MCR, median EFS not reached versus 31 months (2 year EFS 90 vs.51%,  $P = 0.0006$ ).

### Adverse events

The adverse events are summarized in Table 5. Dose decreases were necessary in 16 (18%) and dose interruptions in 31 (34%). Three patients (3%) permanently discontinued IM due to adverse events. All interruptions and reductions were secondary to hematologic toxicities. 60 patients (76%) were able to continue IM at a dose more than 600 mg.

## SUMMARY AND DISCUSSION

In this analysis 32.2% of patients in CP at diagnosis of resistance to IM had a KD mutation with P loop mutations




Figure 1: Mutations detected,  $n = 29$  (32.2%)

Table 1: Base line characteristics ( $n = 90$ )

Variable	Median (range)	No. (%)
Age, year	36 (18-65)	
Sex ratio		2.4:1
Male		64 (71)
Female		26 (29)
Previous therapies apart from IM 400 and hydroxyurea		None
Median time to start IM from diagnosis, months	5 (0.5-20)	
Median duration on IM before resistance, months	18 (3-48)	
Best response to IM 400 mg		
CCR		10 (11.1)
Major PCR		21 (23.5)
Minor cytogenetic response		58 (65.4)
Complete hematologic response		80 (88.8)
Disease groups at IM dose escalation		
Primary hematologic resistance		10 (11.1)
Primary cytogenetic resistance		20 (22.2)
Loss of hematologic response		55 (61.1)
Loss of cytogenetic response		5 (5.5)
Hemoglobin (g/dl)	11.2 (7.9-15.1)	
Total leukocyte count ( $10^9/L$ )	11 (3.7-180)	
Blasts (%)	2 (0-9)	
Basophils (%)	4 (0-12)	
Platelets (%)	2.7 (0.9-11.9)	

IM – Imatinib mesylate; CCR – Complete cytogenetic response; PCR – Partial cytogenetic response

Table 2: Response to dose escalation

Character	Whole group ( $n = 90$ ) (%)	Cytogenetic failure ( $n = 26$ ) (%)	Hematologic failure ( $n = 64$ ) (%)	P
CCR	25 (27.7)	13 (50)	12 (18.7)	0.004
PCR	10 (11.3)	6 (23)	4 (6.2)	0.03
2 years EFS (%)	34	73	22	0.0018
2 years OS (%)	93	100	93	NS

CCR – Complete cytogenetic response; PCR – Partial cytogenetic response; EFS – Event free survival; OS – Overall survival

Table 3: Predictors of major cytogenetic response

Character	Total no	MCR (%)	No MCR (%)	P
Type of resistance				
Primary resistance	31	17 (54.8)	14 (45.1)	0.04
Secondary resistance	59	18 (30.5)	41 (69.4)	
Type of failure				
Hematologic failure	64	16 (25)	48 (75)	<0.0001
Cytogenetic failure	26	19 (73)	7 (27)	
Mutation status				
Mutations present	29	6 (20.5)	23 (79.5)	0.02
Mutations absent	61	29 (47.5)	32 (52.5)	

MCR – Major cytogenetic response

being more common. Unlike in previous studies no clinical or lab parameters were predictive of mutation detection.<sup>[7,8]</sup>

**Table 4: Predictors of EFS**

Character	n	Median EFS (months)	2 years EFS (%)	P
Type of failure				
Cytogenetic failure	26	Undefined	73	0.0018
Hematologic failure	64	13	22	
Response to dose hike				
Major CR	35	41	67	0.0009
No major CR	55	14	20	
Type of resistance				
Primary resistance	31	30	12	0.006
Secondary resistance	59	17	7	
Mutation status				
Present	29	10	27	0.006
Absent	61	25	47	

EFS – Event free survival; CR – Cytogenetic response

**Table 5: Adverse events (n = 90)**

Event	N(%)
Hematologic toxicity (Gr 3-4)	
Anemia	27 (30)
Leucopenia	28 (31)
Neutropenia	35 (44)
Thrombocytopenia	19 (21)
Non-hematologic	
Superficial edema	55 (610)
Musculoskeletal pain	35 (4039)
Fatigue	27 (30)
Anorexia	26 (29)
Rash	24 (27)
Diarrhea	24 (27)
Anorexia	23 (25)
Dyspepsia	13 (14)
Nausea/vomiting	10 (11)
Mucositis/oral ulcers	9 (10)

T315I was much higher (31% of all mutations and 10% of all patients) than previously reported.

Our results with dose escalation are more encouraging than previously reported. However, for those resistant to standard dose IM, Dasatinib is superior to IM dose escalation in terms of cytogenetic responses and disease free survival.

The responses and EFS to IM dose escalation in our study were inferior to that reported previously. We attribute the lower MCR rate in our study to the higher percentage of patients being in hematologic failure at the time of dose escalation. In previously reported studies, patients with hematologic failures at dose escalation had poorer responses and time to treatment failure compared to those with cytogenetic failures.

Presence of mutations predicted for poorer responses

and EFS to dose escalation. There is conflicting data on the prognostic value of mutations. IM dose escalation is likely to be effective only in those harboring no or relatively sensitive KD mutations.

The type of failure at dose escalation and achievement of MCR to dose escalation predicted for improved EFS. Patients with hematologic failure are less likely to have sustained MCRs.

Our results suggest that IM dose escalation is a useful strategy for those with cytogenetic failures. Those with hematologic failures are less likely to benefit from dose escalation. These results emphasize the importance of proper monitoring to detect failures early leading to timely intervention and improved outcomes.

## ACKNOWLEDGMENT

We wish to acknowledge Dabur OncQuest Laboratories, New Delhi where Imatinib resistance mutation analysis were performed.

## REFERENCES

1. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, *et al.* Imatinibmesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. *Blood* 2009;113:2154-60.
2. Baccarani M, Saglio G, Goldman J. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*. 2006;108:1809-20.
3. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. *Lancet Oncol* 2007;8:1018-29.
4. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. *Leukemia*. 2004;18:1321-31.
5. Kantarjian H M, Talpaz M, O'Brien S, Giles, Garcia-Manero G, Faderl S. *et al.* Dose escalation of Imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. *Blood*, 101:473-475, 2003.
6. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. Imatinib Mesylate in Patients with Chronic or Accelerated Phase Chronic Myelogenous Leukemia with Inadequate Hematologic or Cytogenetic Response to Initial Treatment. *Clin Cancer Res* June 2003;9:2092-7.
7. Hochhaus A, Kreil S, Corbin AS. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. *Leukemia*. 2002;16:2190-2196.
8. Barnes DJ, Palaiologou D, Panousopoulou E. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. *Cancer Res*. 2005;65:8912-9.

**How to cite this article:** Rajappa S, Mallavarapu KM, Gundeti S, Paul TR, Jacob RT, Digumarti R. Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. *Indian J Med Paediatr Oncol* 2013;34:221-3.  
**Source of Support:** Nil. **Conflict of Interest:** None declared.